Skip to Content
Merck
CN

Key Documents

View All Documentation

SML1342

API-1

Synonym(s):

4-Amino-5,8-dihydro-5-oxo-8-b-D-ribofuranosyl-pyrido[2,3-d]pyrimidine-6-carboxamide, NSC 177223, NSC177223

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C13H15N5O6
CAS Number:
36707-00-3
Molecular Weight:
337.29
NACRES:
NA.77
PubChem Substance ID:
329825799
UNSPSC Code:
12352200
MDL number:
MFCD18086904
Assay:
≥95% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥95% (HPLC)

Quality Level

100

form

powder

color

white to beige

solubility

DMSO: 1 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

O=C1C(C(N)=O)=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C3=C1C(N)=NC=N3

InChI

1S/C13H15N5O6/c14-10-6-7(20)4(11(15)23)1-18(12(6)17-3-16-10)13-9(22)8(21)5(2-19)24-13/h1,3,5,8-9,13,19,21-22H,2H2,(H2,15,23)(H2,14,16,17)/t5-,8-,9-,13-/m1/s1

InChI key

SPBWHPXCWJLQRU-FITJORAGSA-N

Biochem/physiol Actions

API-1 is a potent and specific Akt/PKB inhibitor.
API-1 is a potent and specific Akt/PKB inhibitor. API-1 binds to pleckstrin homology (PH) domain of Akt and blocks Akt membrane translocation. The compound inhibits all three members of the family Akt1/PKBa, Akt2/PKBb and Akt3/PKBg. API-1 does not inhibit the activation of PKC, SGK, PKA, STAT3, Erk-1/2 or JNK.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
115M4709V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Juhua Zhuang et al.
Oncology research, 26(8), 1257-1265 (2018-02-22)
Hepatocellular carcinoma (HCC) as one of the most refractory cancers leads to high mortality worldwide. Long noncoding RNAs have been widely acknowledged as important biomarkers and therapeutic targets in HCC. In this study, we investigated the effects of long noncoding
Joshua R Huot et al.
Cells, 10(7) (2021-08-08)
It has been demonstrated that inhibiting Notch signaling through γ-secretase inhibitor (GSI) treatment increases myogenesis, AKT/mTOR signaling, and muscle protein synthesis (MPS) in C2C12 myotubes. The purpose of this study was to determine if GSI-mediated effects on myogenesis and MPS

Global Trade Item Number

SKUGTIN
SML1342-5MG04061832451664
SML1342-25MG04061832451657